[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345682-105":59,"doc-detail-345682-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","efficacy-and-safety-of-tirbanibulin-1-ointment-for-actinic-keratosis-at-1-year-follow-up-a-real-life-extension-study","Efficacy and Safety of Tirbanibulin 1% Ointment for Actinic Keratosis at 1-Year Follow-Up - A Real-Life Extension Study","","Tirbanibulin 1% ointment has shown strong short-term efficacy and good tolerability for actinic keratosis (AK) on the face and scalp, but long-term evidence remained limited. This prospective, single-center 12-month extension study reassessed previously treated facial and scalp AKs at baseline, 2 months, and 12 months using clinical and dermoscopic evaluations, focusing on lesions with complete clearance at 2 months. At 12 months, recurrence and new lesion development were tracked alongside safety and patient satisfaction outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-and-safety-of-tirbanibulin-1-ointment-for-actinic-keratosis-at-1-year-follow-up-a-real-life-extension-study/345682/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-and-safety-of-tirbanibulin-1-ointment-for-actinic-keratosis-at-1-year-follow-up-a-real-life-extension-study/345682.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of the 12-month extension study?","Question",{"text":112,"@type":113},"To evaluate long-term efficacy and safety of tirbanibulin 1% ointment for actinic keratosis after prior short-term treatment, using clinical and dermoscopic reassessment at 12 months.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients and lesions selected for long-term analysis?",{"text":117,"@type":113},"Long-term analysis included lesions that achieved complete clinical and dermoscopic clearance at the 2-month follow-up after treatment for 5 consecutive days.",{"name":119,"@type":110,"acceptedAnswer":120},"What safety and tolerability outcomes were observed at 1 year?",{"text":121,"@type":113},"No delayed local or systemic adverse events were reported, and no progression to invasive cSCC was observed during follow-up, with high patient satisfaction reported.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345682,1790499005,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Article  \nEfficacy and Safety of Tirbanibulin 1% Ointment for Actinic Keratosis at 1-Year Follow-Up: A Real-Life Extension Study  \nFederica Li Pomi 1, Mario Vaccaro 2, Michelangelo Rottura 3, Natasha Irrera 3 and Francesco Borgia 2, *  \nAcademic Editor: Andrzej Slominski  \nReceived: 12 April 2026  \nRevised: 11 May 2026  \nAccepted: 20 May 2026  \nPublished: 23 May 2026  \nCopyright: © 2026 by the authors. Published by MDPI on behalf of the Lithuanian University of Health Sciences. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), University of Palermo, 90127 Palermo, Italy; [federicalipomi@hotmail.it](federicalipomi@hotmail.it)  \n2 Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina,  \n98125 Messina, Italy; [mario.vaccaro@unime.it](mario.vaccaro@unime.it)  \n3 Department of Clinical and Experimental Medicine, Section of Pharmacology, University of Messina, 98125 Messina, Italy; [michelangelo.rottura@unime.it](michelangelo.rottura@unime.it) (M.R.); [natasha.irrera@unime.it](natasha.irrera@unime.it) (N.I.)  \n* Correspondence: [fborgia@unime.it](fborgia@unime.it)  \nAbstract  \nBackground: Tirbanibulin 1% ointment has demonstrated short-term efficacy and excellent tolerability in the treatment of actinic keratosis (AK) on the face and scalp. However, data on long-term efficacy are still lacking. Materials and Methods: This prospective, single-center, 12-month extension study included patients with facial and scalp AKs previously treated with tirbanibulin 1% ointment once daily for 5 consecutive days. Long-term analysis was restricted to lesions that had achieved complete clinical and dermoscopic clearance atthe 2-month follow-up. At 12 months, the treated areas were reassessed clinically and dermoscopically. High-resolution images obtained at baseline, 2 months, and 12 months were compared lesion by lesion to distinguish sustained clearance, recurrence at the same anatomical site, and the development of new AKs within the treated field. Results: Thirtyseven patients were reassessed at 12 months. Of the 228 AKs treated at baseline, 116 lesions had achieved complete clearance at 2 months and were therefore eligible for long-term evaluation. At 1 year, 70/116 lesions (60.3%) remained free of recurrence, whereas 46/116 (39.7%) relapsed. Sustained clearance was observed in 35/51 grade 1 lesions (68.6%), 32/57 grade 2 lesions (56.1%), and 3/8 grade 3 lesions (37.5%) . In addition, 35 new AKs developed within the previously treated field. No delayed local or systemic adverse events and no progression to invasive cSCC were observed during follow-up. Patient-reported satisfaction was high, and 94% of patients stated they would be willing to repeat the treatment. Conclusions: Tirbanibulin was associated with sustained lesion clearance atone year, particularly in lower-grade AKs. While recurrence remains relatively common—especially in thicker lesions—the treatment was well tolerated and associated with no delayed adverse effects. Its short application regimen and excellent safety profile support tirbanibulin’s role in the long-term management of field cancerization.  \nKeywords: actinic keratosis; tirbanibulin; tirbanibulin ointment; long-term efficacy; recurrence; real-life; follow-up  \n1. Introduction  \nActinic keratosis (AK) is a common cutaneous intraepithelial neoplasm characterized by the proliferation of atypical keratinocytes within the epidermis, primarily induced by chronic ultraviolet (UV) radiation exposure [1] . It predominantly affects older individuals with fair skin phototypes and typically arises on sun-exposed areas such as the face, scalp,  \nand dorsal hands. AK is widely regarded as a precursor to cutaneous squamous cell carcinoma (cSCC), with reported annual per-lesion malign","cbCaii7oidcNspum","https://ap.wps.com/l/cbCaii7oidcNspum","pdf",1080519,11,"English","# Abstract\n## Background\n## Materials and Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the purpose of the 12-month extension study?\",\"answer\":\"To evaluate long-term efficacy and safety of tirbanibulin 1% ointment for actinic keratosis after prior short-term treatment, using clinical and dermoscopic reassessment at 12 months.\"},{\"question\":\"How were patients and lesions selected for long-term analysis?\",\"answer\":\"Long-term analysis included lesions that achieved complete clinical and dermoscopic clearance at the 2-month follow-up after treatment for 5 consecutive days.\"},{\"question\":\"What safety and tolerability outcomes were observed at 1 year?\",\"answer\":\"No delayed local or systemic adverse events were reported, and no progression to invasive cSCC was observed during follow-up, with high patient satisfaction reported.\"}]","Efficacy and Safety of Tirbanibulin 1% Ointment for Actinic Keratosis at 1-Year Follow-Up - A Real-Life Extension Study | PDF",1790058589,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ea9b46de0fe51c4352aa4fff502779a.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/898c9e701d4e6e3cbe641dd9aeb13633.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29b61cefa637ca85ffe6c72cc307bc00.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c68db4be63f31d8b593fb4fa5e666a2.webp",980,1385]